Efpeglenatide: A Literature Course on What the Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or medication question. It summarises what the published literature on efpeglenatide reports, module by module, and it does not recommend any use, dose or regimen. Each module closes with the limits of the evidence it describes.

Module 1: What Efpeglenatide Is and How It Has Been Studied

Definition and class

Efpeglenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that was developed for once-weekly subcutaneous administration and evaluated in people with type 2 diabetes and in people with obesity, as described in the pharmacokinetic and dose-finding programme reported by researchers in 2020 (PMID 32175655). Unlike GLP-1 analogues built on the human GLP-1 backbone, efpeglenatide was described in the literature as an exendin-based agonist — a modified exendin-4 sequence — conjugated to an immunoglobulin fragment through a flexible linker to extend its circulating half-life (PMID 32175655).

How it has been studied

The published record spans early pharmacokinetic and dose-ranging work (PMID 32175655), an exploratory phase Ib mechanistic comparison against liraglutide (PMID 34172436), the BALANCE trial in weight management with published subgroup analyses stratified by pre-diabetes status, BMI and age (PMID 35042751), phase 3 glycaemic trials including AMPLITUDE-M as monotherapy (PMID 35671039) and the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S trials in suboptimally controlled type 2 diabetes (PMID 37013892), and the AMPLITUDE-O cardiovascular and renal outcome trial (PMID 34215025). Several systematic reviews and meta-analyses have since pooled these datasets (PMID 37885518, PMID 38932865, PMID 39917155).

Forms reported

Across the clinical programme, efpeglenatide was given as a subcutaneous injection. Weekly regimens were used in the cardiovascular outcome trial, where researchers randomly assigned participants to 4 mg or 6 mg once weekly or to placebo (PMID 34215025), while the weight-management programme analysed in the BALANCE subgroup report evaluated both once-weekly and once-every-two-week administration (PMID 35042751).

Limits of the evidence in Module 1: the descriptive literature characterises the molecule and its trial programme, but the peptide was never brought to market, so there is no product labelling, no post-marketing surveillance and no long-term registry data to place alongside the trials. Descriptions of molecular design come from trial publications rather than from dedicated structural papers in this verified set.

Module 2: Mechanism as Described in the Literature

Papers in this set describe efpeglenatide as acting at the GLP-1 receptor, the same target engaged by other incretin-based agents (PMID 32175655). The most direct mechanistic data come from an exploratory, randomised phase Ib study in which researchers compared efpeglenatide with liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes (PMID 34172436). That study was designed to test whether an exendin-based, long-acting agonist produced the same pattern of gastric and islet effects as a daily human GLP-1 analogue, and it reported delayed gastric emptying alongside changes in glucose handling and beta-cell function measures (PMID 34172436).

Whether the cardiovascular and kidney findings of the outcome trial follow from these metabolic actions has been examined statistically rather than experimentally. An exploratory mediation analysis of AMPLITUDE-O asked how much of the observed cardiovascular effect could be statistically accounted for by on-treatment changes in cardiometabolic measures, and reported that only part of the effect was explained by the mediators examined (PMID 42387302). A separate exploratory analysis tested whether concomitant sodium-glucose cotransporter-2 inhibitor use modified the treatment effect, and reported that the cardiovascular and kidney findings appeared broadly consistent in participants using and not using those agents at baseline (PMID 34775781).

Limits of the evidence in Module 2: mechanism here is inferred from human physiological endpoints and from post-hoc statistical modelling, not from receptor-level or animal mechanistic experiments within this verified set. Mediation and subgroup analyses were explicitly labelled exploratory by their authors, were not the trials' primary purpose, and cannot establish causal pathways.

Module 3: Reported Outcomes by Study

The table below summarises what each publication studied and what researchers reported. Nothing in it should be read as a prediction of what would happen in any individual.

Limits of the evidence in Module 3: the phase 3 glycaemic programme was interrupted, and the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S trials were stopped early, which reduced their statistical power (PMID 37013892). The outcome trial enrolled a high-risk population with established cardiovascular or kidney disease and followed participants for a median of 1.81 years, so its findings describe that population over that period and not healthier or longer-followed groups (PMID 34215025). Meta-analyses inherit the limitations of the trials they pool, including heterogeneity of comparators and background therapy (PMID 38932865).

Module 4: Efpeglenatide Side Effects: What Studies Report

Gastrointestinal complaints dominate the published adverse-event record. In the cardiovascular outcome trial, researchers reported that diarrhoea, constipation, nausea, vomiting and bloating occurred more frequently among participants assigned to efpeglenatide than among those assigned to placebo (PMID 34215025). The same pattern appeared in the monotherapy trial, where gastrointestinal events were the most commonly reported adverse events with once-weekly efpeglenatide (PMID 35671039), and in the three later randomised trials in suboptimally controlled type 2 diabetes (PMID 37013892).

Pooled analyses reached the same conclusion. A 2023 meta-analysis of randomised controlled trials reported an increased frequency of gastrointestinal adverse events with efpeglenatide relative to comparators (PMID 37885518), and a 2024 systematic review and meta-analysis of cardiometabolic and safety outcomes likewise reported gastrointestinal events as the principal safety signal (PMID 38932865). A 2025 systematic review covering trials in type 2 diabetes and obesity described the same tolerability profile (PMID 39917155). Delayed gastric emptying reported in the phase Ib mechanistic study provides a physiological context for these complaints (PMID 34172436).

Subgroup and combination analyses also examined safety. The exploratory analysis of participants using and not using sodium-glucose cotransporter-2 inhibitors examined whether the safety and outcome profile differed by that background therapy (PMID 34775781), and the BALANCE subgroup report examined safety by pre-diabetes status, BMI and age (PMID 35042751).

Limits of the evidence in Module 4: trial adverse-event tables capture events during controlled, relatively short exposure in selected participants, and rare events may not appear at all. Because no efpeglenatide product reached the market, there is no pharmacovigilance database to complement the trial data. Reported event frequencies depend on trial design, comparator and background therapy, and none of these publications establishes causation for any individual event.

Module 5: Pharmacokinetics Where Data Exist

The clinical pharmacokinetics of efpeglenatide were characterised in dedicated pharmacokinetic and dose-finding studies in patients with type 2 diabetes, which researchers used to inform the dosing regimens carried into later trials (PMID 32175655). The extended exposure profile reported in that work is what made once-weekly subcutaneous administration feasible, and the 4 mg and 6 mg once-weekly regimens were the ones tested in the cardiovascular outcome trial (PMID 34215025); the weight-management programme also examined once-every-two-week administration (PMID 35042751).

More recently, a population pharmacokinetic analysis pooled data from individuals with obesity and individuals with type 2 diabetes to build a model describing efpeglenatide concentrations and sources of variability between people (PMID 41403449). Population models of this kind are used to describe exposure across populations rather than to prescribe a regimen for any individual.

Limits of the evidence in Module 5: the pharmacokinetic literature was generated in adults enrolled in industry trials, and this verified set contains no paediatric, pregnancy, hepatic-impairment or dedicated drug-interaction pharmacokinetic studies. Model-based exposure estimates are only as reliable as the pooled datasets behind them (PMID 41403449).

Module 6: Regulatory Status, Stated Factually

The following is general regulatory information and not legal advice.

• No approved product. Efpeglenatide is not an approved medicine in the United States or the European Union. It has no approved brand product, no prescribing information and no approved indication. Its clinical programme, including the phase 3 AMPLITUDE trials, was interrupted; the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S trials were reported as having been stopped early (PMID 37013892).
• Research-use-only materials. Peptides supplied to laboratories under "research use only" labelling are intended for in vitro or preclinical laboratory work. Research-use-only status is not an approval, does not signify review of safety or quality for human use, and does not authorise administration to people.
• Compounding. In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that the bulk drug substance be a component of an approved drug, the subject of an applicable monograph, or included on the relevant FDA bulk drug substances list. A peptide that has never been approved and is not on those lists does not meet those statutory conditions.
• Trial evidence versus market authorisation. Published trial results, including the cardiovascular and kidney outcomes reported in AMPLITUDE-O (PMID 34215025), describe what was observed under trial conditions. They are not regulatory approvals, and the existence of positive trial data does not change a compound's legal status.

Limits of the evidence in Module 6: regulatory status changes over time and varies by jurisdiction. None of the papers in this verified set is a regulatory document, and the trial publications do not address national or state-level rules. Readers with legal or clinical questions should consult qualified professionals.

What the Studies Did Not Test

The published efpeglenatide literature is narrower than general interest in GLP-1 receptor agonists. Within this verified set, the trials and reviews did not test:

1. Use in people without diabetes, obesity or high cardiovascular risk. Participants were adults with type 2 diabetes, obesity or established cardiovascular and kidney disease (PMID 34215025, PMID 35042751).
2. Long-term exposure beyond trial duration. The outcome trial followed participants for a median of 1.81 years (PMID 34215025), and other trials were shorter or stopped early (PMID 37013892).
3. Unstudied populations. No paediatric, pregnancy or lactation data appear in this set.
4. Non-injectable routes. The clinical programme used subcutaneous administration (PMID 32175655).
5. Combinations beyond those randomised. Background therapy combinations were limited to those specified in the trials, with one exploratory look at concomitant sodium-glucose cotransporter-2 inhibitor use (PMID 34775781).
6. Head-to-head superiority against currently marketed GLP-1 agents on outcome endpoints. The comparison with liraglutide was an exploratory phase Ib mechanistic study, not an outcome trial (PMID 34172436).

Nothing on this page is an endorsement, instruction or suggestion of use. It is a summary of what researchers reported, including where the evidence stops.

References

• Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (The New England Journal of Medicine, 2021)
• Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes (Diabetes, Obesity & Metabolism, 2020)
• Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study (BMJ Open Diabetes Research & Care, 2021)
• Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials (Cureus, 2023)
• Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial (Circulation, 2022)
• Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials (Diabetes, Obesity & Metabolism, 2023)
• Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial (Diabetes Care, 2022)
• Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review (Cureus, 2025)
• Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis (Journal of Diabetes and Metabolic Disorders, 2024)
• Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes (Frontiers in Pharmacology, 2025)
• Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline (BMJ Open Diabetes Research & Care, 2022)
• Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial (Diabetes, Obesity & Metabolism, 2026)